Across TCGA pan-cancer cohorts, PRR4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRR4 data layer compared with 26 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PRR4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRR4 expression acts as an unfavorable survival marker.
LSCC and LUAD are the cancer types where PRR4 mass-spec protein most reproducibly stratifies survival.